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Abstract: Sensory symptoms are frequent nonmotor complaints in
patients with Parkinson’s disease (PD). However, few investigations
integrally explored the physiology and pathology of the thermonoci-
ceptive pathway in PD. We aim to investigate the involvement of the
thermonociceptive pathway in PD.
Twenty-eight PD patients (16 men, with a mean age and standard
deviation of 65.6 10.7 years) free of neuropathic symptoms and
systemic disorders were recruited for the study and compared to 23
age- and gender-matched control subjects (12 men, with a mean age
and standard deviation of 65.1 9.9 years). We performed skin biopsy,
contact heat-evoked potential (CHEP), and quantitative sensory tests
(QST) to study the involvement of the thermonociceptive pathway in PD.
The duration of PD was 7.1 3.2 (range 2–17 years) years and the
UPDRS part III score was 25.6 9.7 (range 10–48) during the off period.
Compared to control subjects, PD patients had reduced intra-epidermal
nerve fiber (IENF) density (2.48 1.65 vs 6.36 3.19 fibers/mm,
P< 0.001) and CHEP amplitude (18.02 10.23 vs 33.28 10.48mV,
P< 0.001). Twenty-three patients (82.1%) had abnormal IENF densities
and 18 (64.3%) had abnormal CHEP. Nine patients (32.1%) had abnor-
mal thermal thresholds in the feet. In total 27 patients (96.4%) had at least
1 abnormality in IENF, CHEP, or thermal thresholds of the foot,
indicating dysfunctions in the small-fiber nerve system. In control
subjects, CHEP amplitude linearly correlated with IENF density, Yea-Huey Lin, BS , PhD,
ung-Tsang Hsieh, MD, PhD
(P¼ 0.036), suggesting the influences of central components on
thermonociceptive systems in addition to peripheral small-fiber nerves
in PD.
The present study suggested impairment of small-fiber sensory
system at both peripheral and central levels is an intrinsic feature of
PD, and skin biopsy, CHEP, and QST provided an integral approach for
assessing such dysfunctions.
(Medicine 95(10):e3058)
Abbreviations: CHEP = contact heat-evoked potential, CI =
confidence interval, CMAP = compound motor action potential,
IENF = intra-epidermal nerve fiber, NCS = nerve conduction
studies, PD = Parkinson’s disease, QST = quantitative sensory tests,
SAP = sensory action potential, UPDRS = Unified Parkinson’s
Disease Rating Scale, VRS = verbal rating scale.
INTRODUCTION
P arkinson’s disease (PD) is a multidimensional neurodegen-erative disorder with both motor and nonmotor symptoms.1
Sensory complaints, especially pain, are one of the most
common nonmotor symptoms, and more than one-quarter of
PD patients experience ‘‘primary pain’’ related to dysfunction
of the nociceptive system in the early stages of PD when motor
symptoms are not prominent.2,3 However, nerve conduction
studies (NCS) are usually normal in PD patients, except for
large-fiber neuropathy related to long-term exposure to levo-
dopa with increased homocysteine levels and vitamin B12
deficiency.4 Taken together, the symptoms of pain at early
or premotor stage of PD raise the possibility of small-fiber
sensory dysfunctions in either peripheral or central compart-
ments of the nociceptive pathways during the early course of
PD.5
Previous studies have suggested the involvement of small-
fiber pathology in the neurodegenerative process of PD. Skin
biopsies from PD patients have revealed peripheral deafferen-
tation and deposition of phosphorylated a-synuclein in
cutaneous sensory and autonomic nerves.6–9 Heat pain
thresholds and the amplitudes of laser-evoked potentials are
reduced in PD patients compared to control subjects,10–13
implying that central nociceptive processing is altered. How-
ever, a thorough and comprehensive analysis of the involvement
of nociceptive system dysregulation in PD using integrated
strategies that encompass psychophysical, pathological, and
physiological examinations is lacking. Furthermore, the clinical
significance of these alterations in relation to the motor pro-s unknown.
ked potential11 mediated by Ad fibers
ard noninvasive approach to examine
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nociceptive dysfunction as a physiological counterpart of skin
biopsy.14,15 In small-fiber neuropathy, characteristic CHEP
signatures, including the prolongation of latencies and reduction
of amplitudes, parallel the degree of skin nerve degener-
ation.16,17 In addition, CHEP parameters also reflect maladap-
tive plastic changes in the brain of patients with chronic pain.18
We hypothesized that components of the thermonociceptive
system are involved in the degenerative process of PD. We
applied 3 different methods, including skin biopsy, CHEP, and
quantitative sensory testing (QST) to investigate the physiology
and pathology of thermonociceptive dysfunction and their
clinical significance in PD.
PATIENTS AND METHODS
Participants
Twenty-eight patients with idiopathic PD who received
regular follow-up at the movement disorder clinic of National
Taiwan University Hospital (NTUH) were enrolled in the study.
The inclusion criteria were fulfillment of the diagnosis of PD
based on the United Kingdom PD Society Brain Bank clinical
diagnostic criteria19 and an absence of sustained sensory symp-
toms, neuropathic pain, or weakness in the limbs. We excluded
patients who had systemic medical illnesses, such as diabetes
mellitus, chronic liver, and kidney diseases, malignancy, endo-
crine diseases, autoimmune diseases, alcoholism, toxic
exposure, or a family history of neuropathy. None of the patients
had clinically relevant signs of autonomic dysfunction and
mutations in Parkin, PINK1, LRRK2, SCA2, and SCA3 were
previously excluded.20,21 All patients were treated with L-dopa
or a combination with dopamine agonists and had good clinical
responses. L-dopa equivalents were calculated according to
Mo¨ller et al.22 We defined the daily L-dopa dose as the average
daily dosage of L-dopa in the 6 months before entering the
study. We also collected the total cumulative dose of L-dopa
equivalents in the year prior to enrollment. Each patient was
examined using the motor subscale of the Unified Parkinson’s
Disease Rating Scale (UPDRS part III) and Hoehn-and-Yahr
staging. Patients maintained their regular anti-PD medications
and were examined while in the on status. Twenty-three age-
and gender-matched healthy subjects were enrolled for direct
comparisons of the results of skin biopsy and CHEP.
Our study was approved by the Ethics Committee of
NTUH (201106076RB) and followed the Helsinki Declaration
regarding international clinical research involving humans.
Written informed consent was obtained from each participant
before enrollment in the study.
Skin Biopsy, Immunohistochemical Staining, and
Quantification of Epidermal Innervation
A 3-mm skin punch biopsy was taken at the leg 10 cm
proximal to the lateral malleolus in the side with more severe
motor symptoms. The sampled skin tissue was fixed with 2%
paraformaldehyde-lysine-periodate in 0.1M phosphate buffer
overnight. The skin samplewas cut perpendicularly into 50mm
thick sections. Skin sections were immunostained with rabbit
antibody to protein gene product 9.5 (PGP 9.5, 1: 1000;
UltraClone, Isle of Wight, UK) for 16 to 24 hours and were
further incubated with biotinylated goat antirabbit antibody
(Vector, Burlingame, CA) for 1 hour. The avidin–biotin com-
Lin et alplex was sequentially applied for another hour and the reaction
product was demonstrated using chromogen SG (Vector
Laboratories).
2 | www.md-journal.comEpidermal innervation was counted through the depth of
the entire skin section following an established rule by a
clinically blinded trained examiner using an Olympus BX40
microscope (Tokyo, Japan) at 40 magnification. The epider-
mal length along the upper margin of the stratum corneum in
each skin section was measured with ImageJ version 1.43
(Image Processing and Analysis in Java, National Institutes
of Health, Bethesda, MD). The density of IENF was thereby
calculated and expressed as the number of nerve fibers per
millimeter of epidermal length. In our laboratory, the normative
values (meanSD and 5th percentile) of IENF densities at the
distal leg are 11.2 3.7 and 5.9 fibers/mm for subjects aged <
60 years and 7.6 3.1 and 2.5 fibers/mm for subjects aged 60
years. The IENF density lower than 5.9 and 2.5 fibers/mm was
classified as abnormal in these 2 age groups, respectively.23
Records of Contact Heat Evoked Potential
A contact heat evoked potential stimulator (Medoc, Ramat
Yishai, Israel) was used to deliver the heat stimuli.14 The
diameter of the circular thermode is 27mm; the heating rate
is 70 8C/s; and the cooling rate is 40 8C/s. Cooling begins
immediately after the thermode reaches its target stimulus
temperature based on the default algorithms. CHEP was
recorded while subjects sat on a chair, with their eyes closed
and muscle relaxed, in a semi-dark room with the room
temperature controlled at 25 8C. The heat stimulus was applied
to the hairy skin area of the lateral leg around 10 cm proximal to
the lateral malleolus. The skin area was divided into 6 adjacent
nonoverlapping districts. The thermode was moved clockwise
or counter-clockwise across these sites. The heat pulse was
delivered from the 32 to 51 8C. The interstimulus interval was
randomly set to around 20 to 22 s. CHEP was recorded using a
NeuroScan SynAmps 64-channel amplifier and Quik-Caps
system (NeuroScan, El Paso, TX). The recording electrode
was set at Cz. The references were set as bilateral mastoids.
The ground electrode was positioned between FPz and Fz. To
control artifacts, we monitored the electrooculogram from
supra- and infra-orbital electrodes. The impendence of all
electrodes was kept below 5 kV and the online EEG was
sampled at 1000Hz with a bandpass filter at 0 to 300Hz.
Before the formal recording of CHEP, we delivered several
heat stimuli to subjects to avoid startle responses. During the
study, subjects were asked to pay consistent attention to the
stimulus and verbally rated the intensity of pain perception for
3 s after each stimulus using a verbal rating scale (VRS; 0–10),
in which ‘‘0’’ means no sensation, ‘‘4’’ represents the pain
threshold, and ‘‘10’’ corresponds to the intolerable pain. We
recorded CHEP from each leg separately and the order of sides
was balanced among the subjects.
Analysis of CHEP
The offline processing of CHEP waveforms was based on
Scan 4.5 software (NeuroScan, El Paso, TX). The cleaned EEG
signals were cut into epochs from 500 ms before to 1500 ms
after the stimulus onset (0ms). Each epoch was baseline
corrected from 500 to 0 ms and filtered with a bandpass filter
at 0.1 to 30Hz. Epochs with major artifacts were excluded.
CHEPwaveforms were analyzed based on an average of the first
16 artifact-free epochs from the leg of the more affected side. In
normal subjects, CHEP at Cz consisted of an initial negative-
Medicine  Volume 95, Number 10, March 2016wave (N2-wave) followed by a positive-wave (P2-wave) as
described previously.17 We measured the N2-peak latency as
the CHEP latency and the amplitude between the N2-peak and
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
P2-peak as the CHEP amplitude. If both N2-wave and P2-wave
were absent, the CHEP amplitude was defined as the mean
amplitude of the average tracing in the time window between
300 and 800 ms. If only N2-wave or P2-wave was absent, the
CHEP amplitude was the existent P2-wave or N2-wave ampli-
tude. In our laboratory, the normative values from 72 healthy
controls340 years of age were 471.1 42.2 and 534.5 ms for
CHEP latency and 38.1 9.1 and 21.4mV for CHEP amplitude
(meanSD and 5th percentile).
Quantitative Sensory Testing
QSTwas performed according to the algorithm of level in
the lower limb of more severely affected side using a Thermal
Sensory Analyzer (Medoc, Ramat Yishai, Israel) as described
before.24 Thermal thresholds according to the algorithm of level
recorded on the foot dorsum were expressed as the warm
threshold temperature and cold threshold temperature. Vibra-
tory thresholds were measured with similar algorithms, and
expressed in micrometers. These values were compared with
normative values for the age, which had previously been
documented.24
Nerve Conduction Study
NCS was performed in bilateral sural, peroneal, and tibial
nerves with a Viking Select Electromyographer (Nicolet, MD)
following established methods.25 Bilateral sural, peroneal, and
tibial nerves were studied. Abnormal results in NCS were
defined as having reduced amplitude of compound motor
action potential (CMAP) or sensory action potential (SAP),
prolonged distal latencies, slowing of the nerve conduction
velocity.25
Statistical Analyses
Data were interpreted according to our previously
described normative databases. The results of skin biopsy
and CHEP for the PD patients were further compared to those
of age- and gender-matched subjects. Numerical variables
were expressed as the mean standard deviation of the mean.
For variables following a Gaussian distribution, data was
compared using 2-tailed t test. Regression analysis was per-
formed to evaluate the correlations between variables and the
correlation was expressed graphically with the slope of
regression line and its 95% confidence interval (CI). The
correlation was further explored with multivariate analysis,
and the covariance of the model (R2) and the standardized
correlation coefficient were presented. We performed all the
analysis by Stata (StataCorp LP, College Station) and Prism
(GraphPad Software, San Diego) software. A P value < 0.05
was considered significant.
RESULTS
Clinical Characteristics
The mean age of the 28 PD patients was 65.6 10.7 (range
44–88) years and the mean disease duration was 7.1 3.2 (2–
17) years. Sixteen of the patients were men. The detailed
clinical features of the PD patients enrolled in this study are
summarized in Table 1. The mean UPDRS part III score was
25.6 9.7 (10–48) during the off period. The mean L-dopa
equivalent dose was 601.8 274.7 (150–1200) mg/day and the
Medicine  Volume 95, Number 10, March 2016total cumulative L-dopa equivalent dose the year before enroll-
ment was 189.2 82.5 (54–360) g/year. The results of neuro-
logical examinations were unremarkable in 21 patients (75.0%),
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.and a mild but symmetrical decrease in the deep tendon reflex of
the lower limbs was observed in 7 patients (25.0%). All of these
patients had full muscle power and did not reveal subjective
sensory impairment.
The independent control group for skin biopsy and CHEP
comparisons comprised 23 age- and gender-matched healthy
subjects, including 12 men. The mean age was 65.1 9.9 years
(P¼ 0.73 for gender and P¼ 0.86 for age).
Nerve Conduction Study and Quantitative
Sensory Testing
For large-fiber nerve functions according to NCS of the
lower limbs, the results were within normal limits in 24 patients
(85.7%). The other 4 patients had normal sural nerve studies but
mildly reduced amplitudes of compound muscle action poten-
tials in peroneal or tibial nerves. For the psychophysical
parameters of both small-fiber and large-fiber nerves assessed
by QST, 9 patients (32.1%) had abnormal thermal thresholds in
the foot (all 9 with elevated warm thresholds and 1 with elevated
cold thresholds) and 16 patients (57.1%) had elevated vibratory
thresholds in the lateral malleolus.
Skin Biopsy
Skin biopsy was performed to investigate the pathology of
small-diameter sensory nerves. In control subjects, intra-epi-
dermal nerve fibers (IENFs) with a typical varicose appearance
arose from the subepidermal nerve plexuses, and dermal nerve
fibers exhibited dense and linear immunoreactivities
(Figure 1A). In contrast, IENFs were markedly reduced and
dermal nerve fibers fragmented in PD patients (Figure 1B),
which is consistent with nerve degeneration. IENF densities
were significantly lower in PD patients compared to control
subjects (2.48 1.65 vs 6.36 3.19 fibers/mm, P< 0.001,
Figure 1C). Among the 28 PD patients, 23 (82.1%, Table 1)
had IENF densities lower than the 5th percentile of the norma-
tive data: 6 cases (6/6) with Hoehn-and-Yahr stage 1 in the off
state, 10 (10/11) with stage 2, 6 (6/8) with stage 3, 1 (1/2) with
stage 4, and none (0/1) with stage 5.
Contact Heat Evoked Potentials
Figure 2A shows the grand average of CHEPs from PD
patients and age- and gender-matched control subjects. In
controls, CHEPs had well-defined biphasic waveforms with
an initial negative peak (N2-wave) followed by a positive peak
(P2-wave) (Figure 2A). The CHEP amplitude was attenuated in
PD patients (Figure 2B). Furthermore, the CHEP amplitude
was significantly reduced in PD patients compared to control
subjects (18.02 10.23 vs 33.28 10.48mV, P< 0.001,
Figure 2C), and 18 patients (64.3%) had abnormal CHEP
parameters. There was no difference in the N2-wave latencies
between PD cases and controls (P¼ 0.41) or any difference in
CHEP amplitude between the side with more severe motor
symptoms and the side with less involvement (18.02 10.23 vs
16.36 11.31mV, P¼ 0.16). Upon contact heat stimulation,
the mean intensity of pain perception on the verbal rating scale
(VRS) was 4.4 1.7, which is in the range of mild to
moderate pain.
Correlation Between Clinical and
Thermonociceptive Parameters
Pathophysiology of Small-Fiber Sensory System in PDAll patients except 1 (96.4%) had at least 1 abnormality in
IENF density, CHEP amplitude, or thermal thresholds in the
foot, providing quantitative evidence for small-fiber physiology
www.md-journal.com | 3
TABLE 1. Clinical Data, Skin Innervation, and Contract Heat Evoked Potentials of Patients with Parkinson’s Disease
Patient Age, Sex
Disease
Duration,
(Y)
UPDRS III
(On)
UPDRS III
(Off)
H-Y
Stage
(On)
H-Y
Stage
(Off)
Current
L-Dopa
Dose
(mg/day)
Cumulative
L-Dopa
Dose
(g/Y)
IENF
Density
(Fibers/mm)
N2-P2
Amplitude
of CHEP
(mV)
1 44 M 6 10 18 1 2 600 216 3.38 29.08
2 51 M 8 8 28 1 2 400 126 4.79 31.39
3 52 F 4 6 15 1 2 400 101.25 6.26 20.21
4 53 F 3 8 14 1 1 300 108 2.93 40.44
5 54 F 8 25 32 3 4 1200 360 5.87 26.16
6 57 F 5 5 18 1 2 150 54 0.71 12.22
7 57 M 7 18 25 2 2 450 121.5 4.61 15.55
8 58 F 5 12 20 2 2 600 216 1.73 12.01
9 59 F 7 6 12 1 1 150 54 3.42 16.69
10 59 M 3 20 30 2 3 600 195.75 2.32 3.43
11 60 M 17 15 32 2 3 800 288 3.30 7.09
12 63 M 5 7 12 1 1 600 135 1.27 17.47
13 65 F 8 20 34 2 3 700 234 1.58 17.72
14 65 F 13 28 32 3 3 800 288 3.67 26.11
15 65 M 9 20 32 1 2 600 216 1.76 23.12
16 66 M 4 6 13 1 1 300 90 1.18 21.22
17 69 M 6 17 28 2 2 800 252 1.23 24.25
18 69 F 6 7 15 1 1 600 189 1.48 27.02
19 71 F 12 20 30 2 3 600 216 1.34 28.45
20 71 M 9 20 30 2 3 800 252 3.51 12.62
21 74 M 5 36 42 3 4 800 180 0.44 11.85
22 74 F 2 6 10 1 1 300 108 2.15 36.46
23 75 M 8 17 33 2 3 1000 270 0.89 2.52
24 77 M 8 20 26 2 2 800 234 1.51 10.38
25 78 M 6 18 24 2 2 300 108 1.86 4.05
26 81 M 6 20 28 2 2 600 189 0.62 14.90
27 82 F 8 40 48 4 5 1200 351 4.92 3.37
28 88 M 10 28 36 3 3 400 144 0.74 8.84
CHEP¼ contact heat evoked potential, F¼ female, H-Y stage¼Hoehn-and-Yahr stage, IENF¼ intraepidermal nerve fiber, M¼male, UPDRS
Lin et al Medicine  Volume 95, Number 10, March 2016and pathology. First, we investigated the relationship between
skin innervation, CHEP amplitude, and the thermal threshold in
the foot, and analyzed the effects of age, gender, disease
duration, and anti-PD drugs on these parameters using univari-
ate linear regression. In PD, there was no relationship between
CHEP amplitude and IENF density (P¼ 0.312, Figure 3A)
although CHEP amplitude and IENF density both negatively
correlated with age (r¼0.414, P¼ 0.021 and r¼0.079,
P¼ 0.005, respectively). The warm threshold in the foot posi-
tively correlated with the daily dose and yearly cumulative dose
of L-dopa equivalent (r¼ 0.004 and 0.012, P¼ 0.019 and 0.030,
respectively). These findings contrasted with the normal control
group in which the CHEP amplitude positively correlated with
IENF density (r¼ 2.698, P< 0.001, Figure 3B) in addition to
the correlation of CHEP amplitude and IENF density with age
(r¼0.749, P< 0.001 and r¼0.233, P< 0.001, respect-
ively). When simultaneously considering the effects of age
and gender in the multivariate linear regression model, CHEP
amplitude only significantly correlated with IENF density in the
control group (r¼ 1.637, P¼ 0.011 for IENF density; R2¼ 0.76
III¼Unified Parkinson’s Disease Rating Scale part III.and P< 0.001 for the model).
Next, we examined the relationship between the small-
fiber sensory dysfunction and the motor symptoms of PD. The
4 | www.md-journal.comCHEP amplitude negatively correlated with the Hoehn-and-
Yahr stages and UPDRS part III scores in both the on and off
state (Figure 4A–D), whereas the warm threshold in the foot
positively correlated with Hoehn-and-Yahr stages and UPDRS
part III scores in both the on and off state. There was no
correlation between IENF density and PD motor severity. In
multivariate linear regression analysis incorporating age, gen-
der, daily L-dopa equivalent dose, disease duration of PD, and
CHEP amplitude or warm threshold in the foot as independent
variables, CHEP amplitude still negatively correlated with
Hoehn-and-Yahr stages in the off state (r¼0.032,
P¼ 0.036 and R2¼ 0.69, P< 0.001 for the model).
To further explore whether peripheral or central
parameters were associated CHEP in PD, the multivariate
regression model was applied with CHEP amplitude as depen-
dent variable, and age, gender, IENF density and motor scores,
that is, Hoehn-and-Yahr stage as independent variables. In this
model, IENF density represented the peripheral deafferenta-
tion and Hoehn-and-Yahr stage served as a surrogate marker of
central effects of PD. Hoehn-and-Yahr stages in the off state
was the only factor correlated with CHEP amplitude
(r¼4.26, P¼ 0.031 and R2¼ 0.41, P¼ 0.013 for the model)
(Table 2).
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FIGURE 1. Skin innervation in Parkinson’s disease. Skin sections from the distal leg of an age- and gender-matched control subject (A) and
a representative patient with Parkinson’s disease (B) were immunostained with antiprotein gene product 9.5 (PGP 9.5). (A) In the
epidermis (epi) of the control subject, intraepidermal nerve fibers (arrows) ascended from the subepidermal nerve plexus (snp) in the
dermis (derm). (B) In the skin of the Parkinson’s disease patient, intraepidermal nerve fibers were reduced and the subepidermal nerve
plexus fragmented, suggesting nerve degeneration. (C) The intraepidermal nerve fiber density was markedly reduced in the legs of
con

exu
Medicine  Volume 95, Number 10, March 2016 Pathophysiology of Small-Fiber Sensory System in PDDISCUSSION
In the present study, we reported the integrated data of
CHEP, skin biopsy, and QST in PD patients who were free
of neuropathic sensory symptoms and systemic diseases.
Almost all enrolled PD patients (96.4%) had quantitative evi-
dence of dysfunction in the thermonociceptive system based on
reduced IENF density, reduced CHEP amplitude, and elevated
warm threshold in the foot. Furthermore, CHEP amplitude and
warm threshold in the foot correlated with the severity of PD
motor dysfunction, and CHEP amplitude reflects the motor
severity independent of age, gender, and the dose of anti-PD
medications.
We observed a high prevalence of small-fiber sensory
dysfunction in PD based on combined neurophysiological,
pathological, and psychophysical assessments. This finding
provides objective evidence and explanations for previous
epidemiological studies indicating a high prevalence of pain
in PD patients.26,27 The exclusion of systemic diseases, toxin
exposure, and organic brain lesions in the present study ascer-
Parkinson’s disease patients compared to age- and gender-matched
9.5¼ antiprotein gene product 9.5, snp¼ subepidermal nerve pltained that the small-fiber physiology and pathology was
intrinsic to the disease course of PD. Although recent studies
have emphasized the relationship between the use of levodopa
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.and peripheral neuropathy,4,28 the absence of a correlation
between L-dopa equivalent doses and the IENF density or
CHEP parameters, as well as the preservation of large fiber
physiology in our PD patients, suggest that the small-fiber nerve
degeneration and thermonociceptive pathophysiology were
independent of the use of anti-PD medications and an integral
part of the neurodegeneration that occurs in PD. Postmortem
pathological studies have revealed progressive pathological
changes in the thermonociceptive pathway at multiple levels
in PD.26 Progressive involvement of Lewy body deposition in
PD brains could affect the structures of the medial and lateral
pain processing systems, that is, the locus coeruleus, nucleus
raphe magnus, and gigantocellular reticular nucleus, which are
key areas in the descending regulation of pain,29 as well as the
anterior cingulated cortex, amygdala, and prefrontal cortex,
which are associated with motivational and emotional aspects
of pain.27 In addition to the cutaneous denervation being
pathological evidence of primary thermonociceptive nerves,8,9
recent studies in PD have demonstrated the involvement of
trol subjects. Scale bar¼ 25mm for (A) and (B). :P<0.001. PGP
s.medium-sized multipolar projecting neurons at lamina I of the
spinal cord, the initiating component of the spinothalamic
tract.30,31 According to Braak’s pathology staging, many of
www.md-journal.com | 5
FIGURE 2. Contact heat-evoked potentials in Parkinson’s disease.
Grand average of CHEP in control subjects (A) and patients with
Parkinson’s disease (B). (A) In the control subjects, the CHEP
evoked by stimulation of the leg revealed a well-defined nega-
tive-positive (N2-P2) biphasic waveform. (B) In patients with
Parkinson’s disease, the amplitude of the N2-P2 wave was reduced
and the peak-latency of the N2 wave prolonged compared to
controls. (C) The N2-P2 amplitude of CHEP was significantly
smaller in patients with Parkinson’s disease compared to the
FIGURE 3. Loss of correlation between the amplitude of contact
heat evoked potentials and skin innervation in Parkinson’s disease.
No relationship was found between the N2-P2 amplitude of CHEP
evoked by stimulation of the leg and the intraepidermal nerve
fiber density in the leg of patients with Parkinson’s disease. (B) In
the age- and gender-matched controls, the N2-P2 amplitude of
CHEP evoked by stimulation of the leg highly correlated with the
Lin et al Medicine  Volume 95, Number 10, March 2016these structures are affected in the early course of PD, even
before the obvious involvement of motor function.29,31 All of
these pathological changes may contribute to abnormalities in
skin innervation, CHEP amplitude, and thermal thresholds in
PD patients.
This study demonstrates the feasibility of the CHEP as a
noninvasive clinical examination for assessing thermonocicep-
tive dysfunctions in PD. The CHEP amplitude was reduced in
PD patients compared to controls, and 64.3% patients had
reduced CHEP amplitudes compared to normative values from
age- and gender-control subjects. : P<0.001; CHEP¼ contact
contact heat evoked potential.healthy subjects of similar age and gender. We found no
difference in CHEPs between the sides regarding the severity
of motor dysfunction. These findings extended a previous study
6 | www.md-journal.comthat reported reduced N2-P2 amplitude of laser-evoked poten-
tials in PD regardless of the clinically affected side.12 Given that
CHEP records brain activities after heat pain stimuli on skin as
conveyed by the thermonociceptive pathway, CHEP could
detect dysfunctions in this pathway at either the peripheral
and central level. Previous studies have showed a correlation
between reduced CHEP amplitude and decreased IENF density
in diseases of pure peripheral nerves, that is small-fiber neuro-
pathy of different etiologies.17,32 In the present study, CHEP
amplitude was only correlated with the IENF density in the
control group. Despite significant reduction of IENF density
and CHEP amplitude in PD patients, the relationship between
CHEP amplitude and IENF density altered, that is, CHEP
amplitude was associated with Hoehn-and-Yahr stage in PD.
These observations suggest the change in CHEP amplitude was
intraepidermal nerve fiber density of the leg (P<0.001).
CHEP¼ contact heat evoked potential.affected not only by peripheral deafferentation but also central
components in PD, that is, the striatum.29,30,33 Recently, ima-
ging studies have demonstrated striatal activations by heat pain
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 4. The relationship between contact heat evoked potential and motor dysfunction in patients with Parkinson’s disease. The
N2-P2 amplitude of CHEP evoked by stimulation of the leg negatively correlated with the on- and off-time Hoehn-and-Yahr scales
(r¼5.83, P¼0.012 and r¼4.57,P¼0.015) (A and B), and the on- and off-time of UPDRS part III (r¼0.46,P¼0.026 and r¼0.49,
sta
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an unexplored role of the striatum in nociceptive proces-
sing.33,34 Taken together, the present report might provide
evidence of the central effects of PD contributing to the
alterations of CHEP amplitude. In this study, we also observed
a correlation between CHEP amplitudes and the warm threshold
in the foot and motor severity in PD as measured by Hoehn-and-
Yahr stages and UPDRS part III scores. Even after considering
the confounding effects of age, gender, anti-PD medication
dose, and disease duration of PD, the CHEP amplitude still
highly correlated with Hoehn-and-Yahr stages. Compatible
with previous literatures, our study showed no correlation
P¼0.012) (C and D). CHEP¼ contact heat evoked potential, H&Y
Rating Scale.between the cutaneous sensory innervations and motor dysfunc-
tion in PD patients,9 suggesting that separate pathological
processes underlie the central motor system and peripheral
TABLE 2. Multiple Linear Regression Models for Contact Heat Ev
Group CHEP Amplitude R, P Age
Controls 0.76, <0.001
 0.39, 0.048
Parkinson’s disease 0.41, 0.013
 0.20, 0.339
In this model, the CHEP amplitude of controls or patients with Parkinson’s
and Hoehn-and-Yahr stages in the off state (Parkinson’s disease only) wer
CHEP¼ contact heat evoked potential, IENF¼ intra-epidermal nerve fib
P¼ for R or t, R¼ correlation coefficient based on the model of multiple
model. ¼ statistically significant.P< 0.05.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.thermonociceptive nerves in PD.35 Unlike IENF density, CHEP
represents integrated brain responses to heat-pain stimuli,
including the activation of somatosensory areas, insula, and
cingulated cortex, which are further influenced by deep struc-
tures of the thalamus, basal ganglion, amygdala, and brain-
stem.33,36,37 Many of these structures become progressively
involved in PD; thus, the changes in CHEP amplitude might
potentially reflect the motor progression of PD.29,38 A recent
study investigating laser-evoked potentials in PD patients with
shoulder muscular pain did not show a relationship between N2-
P2 amplitude and motor symptom severity.10 Possible reasons
for the discrepancy between this study and ours include differ-
ge¼Hoehn-and-Yahr scales, UPDRS¼Unified Parkinson’s Diseaseences in motor status on recordings, sensory symptoms, heat
pain stimuli used, the location at which the stimulus was
applied, and disease duration. These issues await further studies
oked Potential (CHEP) Amplitude
t, P
Gender IENF Density Hoehn-and-Yahr stage, Off
5.29, 0.050 1.64, 0.011 –
6.07, 0.086 0.64, 0.631 4.26, 0.031
disease was set as the dependent variable, and age, gender, IENF density,
e set as independent variables.
er.
linear regression, t¼ t value for the coefficient of each parameter in the
www.md-journal.com | 7
for clarification. In addition to CHEP, the warm threshold in the
foot also correlated with motor severity in our PD patients.
Similar to CHEP, the thermal thresholds assess an integral
outcome of thermal sensations. Taken together with recent
studies showing an improvement in temperature sensation after
deep brain stimulation of the subthalamic nucleus in PD,39,40
these observations suggest that the dysfunction in the thermo-
nociceptive networks might be associated with impairment of
the cortical-striatal-nigral dopaminergic circuits.
There are several limitations in this study. For the studied
PD patients, we excluded patients with sustained sensory
symptoms, neuropathic pain, or weakness in the limbs to avoid
confounding etiologies causing neuropathic disorders or pain.
The study therefore did not address the relationships between
the clinical sensory symptoms and the assessed thermonoci-
ceptive dysfunctions. Another aspect is the small sample size of
PD patients, which hinders us from further stratification of
patients with different motor severity. Finally, we did not check
the serum level of vitamin B12 in these PD patients, which
might underestimate the effects of levodopa use on the risk of
neuropathy. However this limitation would not significantly
impact our findings since most reported neuropathy related to
levodopa use was mainly large-fiber neuropathy,4 and we had
adjusted the cumulative dosage of levodopa in our analysis.
Nevertheless, the present study documents that the small-fiber
physiology and pathology of the thermonociceptive pathway at
Lin et alboth the peripheral and central levels are intrinsic features of
PD. Skin biopsy, CHEP, and QST provide an integral and
sensitive approach for assessing such dysfunctions.
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